MX2022013064A - Nuevos derivados de imidazolona como inhibidores de proteinas cinasas en particular cinasa 1a regulada por fosforilacion de la tirosina de especificidad dual (dyrk1a), cinasa 1 similar a las citolisinas dependientes del colesterol (clk1) y/o cinasa 4 similar a las citolisinas dependientes del colesterol (clk4). - Google Patents
Nuevos derivados de imidazolona como inhibidores de proteinas cinasas en particular cinasa 1a regulada por fosforilacion de la tirosina de especificidad dual (dyrk1a), cinasa 1 similar a las citolisinas dependientes del colesterol (clk1) y/o cinasa 4 similar a las citolisinas dependientes del colesterol (clk4).Info
- Publication number
- MX2022013064A MX2022013064A MX2022013064A MX2022013064A MX2022013064A MX 2022013064 A MX2022013064 A MX 2022013064A MX 2022013064 A MX2022013064 A MX 2022013064A MX 2022013064 A MX2022013064 A MX 2022013064A MX 2022013064 A MX2022013064 A MX 2022013064A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- group
- sup
- compound
- phenyl group
- Prior art date
Links
- 101100003180 Colletotrichum lindemuthianum ATG1 gene Proteins 0.000 title 1
- 101150086683 DYRK1A gene Proteins 0.000 title 1
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical class O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000027412 CDKL5-deficiency disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 208000033180 Monosomy 22q13.3 Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000006880 Phelan-McDermid syndrome Diseases 0.000 abstract 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000036760 body temperature Effects 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940014144 folate Drugs 0.000 abstract 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003959 neuroinflammation Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a un compuesto de fórmula (I) S N N HN O R NH 1 (I) R2 en donde R1 representa un grupo alquilo (C1-C6), un anillo espirobicíclico (C5-C11), un grupo fenilo fusionado, un fenil sustituido, un grupo R'-L-, en donde L es ya sea un enlace sencillo o un grupo alcandiilo (C1-C3), y R' representa un grupo cicloalquilo (C3-C8), un grupo cicloalquilo (C6-C10) puenteado, un grupo heterocicloalquilo (C3-C8), o un grupo heteroarilo (C3-C8), o un grupo R'-L- en donde L es un grupo alcandiilo (C1-C3), y R' es un grupo fenilo opcionalmente sustituido, y en donde R2 representa un átomo de hidrógeno o un grupo alquilo (C1-C3) o cualquiera de sus sales farmacéuticamente aceptables. La presente invención se refiere además a una composición que comprende un compuesto de fórmula (I) y un proceso para manufacturar tal compuesto, así como también sus intermediarios de síntesis. También se refiere a tal compuesto para uso como un medicamento, en particular en el tratamiento y/o prevención de déficits cognitivos asociados con déficits cognitivos asociados al síndrome de Down; enfermedad de Alzheimer; demencia; tauopatías; Enfermedad de Parkinson; trastorno por deficiencia de CDKL5; síndrome de Phelan-McDermid; autismo; diabetes tipo 1 y tipo 2; metabolismo anormal del folato y la metionina; osteoartritis; Distrofia muscular de Duchenne; varios cánceres; neuroinflamación, anemia e infecciones virales y unicelulares y para regular la temperatura corporal.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305421.8A EP3904354A1 (en) | 2020-04-30 | 2020-04-30 | New imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4 |
| EP21305361 | 2021-03-24 | ||
| PCT/EP2021/061349 WO2021219828A1 (en) | 2020-04-30 | 2021-04-29 | New imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013064A true MX2022013064A (es) | 2023-04-12 |
Family
ID=75690302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013064A MX2022013064A (es) | 2020-04-30 | 2021-04-29 | Nuevos derivados de imidazolona como inhibidores de proteinas cinasas en particular cinasa 1a regulada por fosforilacion de la tirosina de especificidad dual (dyrk1a), cinasa 1 similar a las citolisinas dependientes del colesterol (clk1) y/o cinasa 4 similar a las citolisinas dependientes del colesterol (clk4). |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230167104A1 (es) |
| EP (1) | EP4143185A1 (es) |
| JP (1) | JP2023523788A (es) |
| KR (1) | KR20230005197A (es) |
| CN (1) | CN115515953A (es) |
| AU (1) | AU2021266141A1 (es) |
| BR (1) | BR112022021442A2 (es) |
| CA (1) | CA3174844A1 (es) |
| CL (1) | CL2022002996A1 (es) |
| CO (1) | CO2022015361A2 (es) |
| IL (1) | IL297767B1 (es) |
| MX (1) | MX2022013064A (es) |
| WO (1) | WO2021219828A1 (es) |
| ZA (1) | ZA202210885B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021114314A1 (en) * | 2019-12-14 | 2021-06-17 | Tongji University | Novel heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005082901A1 (en) * | 2004-02-25 | 2005-09-09 | Smithkline Beecham Corporation | Novel chemical compounds |
| KR100875408B1 (ko) * | 2004-10-14 | 2008-12-23 | 에프. 호프만-라 로슈 아게 | Ｃｄｋ1 항증식성 활성을 갖는 1,5-나프티리딘 아졸리디논 |
| US7304074B2 (en) * | 2005-04-05 | 2007-12-04 | Hoffmann-La Roche Inc. | Substituted 1,5-naphthyridine azolinones |
| JP2009528384A (ja) * | 2006-03-02 | 2009-08-06 | スミスクライン・ビーチャム・コーポレイション | Ｐｉ３キナーゼ阻害剤として用いるためのチアゾロン |
| FR2919608B1 (fr) | 2007-08-01 | 2012-10-05 | Univ Rennes | Derives d'imidazolones,procede de preparation et applications biologiques |
-
2021
- 2021-04-29 IL IL297767A patent/IL297767B1/en unknown
- 2021-04-29 WO PCT/EP2021/061349 patent/WO2021219828A1/en active Application Filing
- 2021-04-29 AU AU2021266141A patent/AU2021266141A1/en active Pending
- 2021-04-29 KR KR1020227038151A patent/KR20230005197A/ko active Search and Examination
- 2021-04-29 CN CN202180031731.0A patent/CN115515953A/zh active Pending
- 2021-04-29 JP JP2022566163A patent/JP2023523788A/ja active Pending
- 2021-04-29 BR BR112022021442A patent/BR112022021442A2/pt unknown
- 2021-04-29 CA CA3174844A patent/CA3174844A1/en active Pending
- 2021-04-29 EP EP21721939.3A patent/EP4143185A1/en active Pending
- 2021-04-29 US US17/997,324 patent/US20230167104A1/en active Pending
- 2021-04-29 MX MX2022013064A patent/MX2022013064A/es unknown
-
2022
- 2022-10-03 ZA ZA2022/10885A patent/ZA202210885B/en unknown
- 2022-10-27 CL CL2022002996A patent/CL2022002996A1/es unknown
- 2022-10-28 CO CONC2022/0015361A patent/CO2022015361A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2022015361A2 (es) | 2022-11-08 |
| EP4143185A1 (en) | 2023-03-08 |
| ZA202210885B (en) | 2024-02-28 |
| IL297767A (en) | 2022-12-01 |
| AU2021266141A1 (en) | 2022-12-01 |
| US20230167104A1 (en) | 2023-06-01 |
| KR20230005197A (ko) | 2023-01-09 |
| CL2022002996A1 (es) | 2023-05-26 |
| WO2021219828A1 (en) | 2021-11-04 |
| JP2023523788A (ja) | 2023-06-07 |
| CN115515953A (zh) | 2022-12-23 |
| BR112022021442A2 (pt) | 2022-12-13 |
| IL297767B1 (en) | 2024-02-01 |
| CA3174844A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6125571B2 (ja) | ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法 | |
| CN102947289B (zh) | 芳基乙炔基衍生物 | |
| JP6761821B2 (ja) | 代謝性グルタミン酸受容体モジュレーターとしてのエチニル誘導体 | |
| JP6437544B2 (ja) | 置換キナゾリン−４−オン誘導体 | |
| WO2017096301A1 (en) | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1) | |
| JP6649540B2 (ja) | 置換されたヘテロアリール化合物および使用方法 | |
| MX2013003620A (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3. | |
| JP2011529073A (ja) | キナーゼ調節因子として有用な縮合ヘテロ環化合物 | |
| WO2008039359A2 (en) | Bicyclic pyrimidine kinase inhibitors | |
| AU2007254491A1 (en) | Compositions and methods for FGF receptor kinases inhibitors | |
| CA2630360A1 (en) | Substituted bicyclic pyrimidone derivatives | |
| JP6908623B2 (ja) | テトラヒドロイソキノリン誘導体 | |
| AU2003237235A1 (en) | Calcium receptor modulating agents | |
| AU2007339164A1 (en) | 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhbitors | |
| US20200281951A1 (en) | Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | |
| MX2022013064A (es) | Nuevos derivados de imidazolona como inhibidores de proteinas cinasas en particular cinasa 1a regulada por fosforilacion de la tirosina de especificidad dual (dyrk1a), cinasa 1 similar a las citolisinas dependientes del colesterol (clk1) y/o cinasa 4 similar a las citolisinas dependientes del colesterol (clk4). | |
| CA3168211A1 (en) | Pyrrolopyridine derivative and use thereof for preventing or treating protein kinase related disease | |
| JP2010522226A (ja) | 酵素ｐｄｅ７及び／又はｐｄｅ４の二重阻害化合物、薬剤組成物および利用法 | |
| EP3953348A1 (en) | Compounds, compositions and methods | |
| AU2013303824A1 (en) | Bicyclic heteroaryl cycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinases (SYK) | |
| JP6089104B2 (ja) | アリールエチニル誘導体 | |
| JP6415982B2 (ja) | 複素環化合物 | |
| OA10202A (en) | Positive inotropic and lusitropic pyrroloquinolinone derivatives | |
| US20220213089A1 (en) | Inhibiting cyclic amp-responsive element-binding protein (creb) | |
| US7893064B2 (en) | Hydrazone derivatives as kinase inhibitors |